Genflow Biosciences calls shareholder meeting to approve potential equity raise

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) has called a general meeting on 2 March to seek shareholder approval for the issue of up to 189 million new shares, equivalent to 38% of its issued capital. The potential equity raise, if undertaken, would be conducted on a non-preemptive basis through one or more private placements. Proceeds would support the company’s pipeline programmes in metabolic dysfunction-associated steatohepatitis, animal health, glaucoma and intellectual property. No agreements with investors have yet been made.